CAAM

What CAAM does

CAAM (Centri Associati di Allergologia Molecolare - Studio Medico Associato) is a private Italian medical practice founded in October 2013, headquartered in Sermoneta (province of Latina) with a legal seat in Latina and an operational site in Rome. The organization is owned by five founding allergology specialists and operates Sermolab S.r.l. as its wholly-owned clinical and research laboratory. CAAM specializes in molecular allergology diagnostics, serving individual patients (pediatric through geriatric) seeking precise IgE-mediated allergy diagnosis and personalized therapy, as well as multi-specialty centers, laboratories, clinicians, and research institutions that integrate CAAM's platform into their workflows.

The company runs an integrated diagnostic and data platform built on three technology layers: biotechnology (allergen identification and characterization), micro and nanotechnology (the FABER multiplex IgE test using chemically activated nanoparticles conjugated with hundreds of purified allergenic molecules and extracts), and ICT (the Allergome web platform, InterAll electronic health record, CDRS dynamic reporting system, and ReTiME data module). Core commercial products include the FABER 244-122-122 test, the newer ALEX3 test analyzing 300 allergens from a single blood draw, and CDRS/CDRS PRO patient and professional visualization tools. CAAM also maintains research collaborations with IBBR-CNR (Napoli), the Medical University of Vienna, the University of Salzburg, the Academic Medical Center Amsterdam, and Allergy Data Laboratories S.r.l., and operates an international FABER partner network spanning at least nine countries.

Revenue is generated primarily through pay-as-you-go diagnostic testing at Sermolab S.r.l. and CDRS subscription fees (free for the first year after a test, with paid extensions), supplemented by network integration arrangements with healthcare facilities and international partners. Patient acquisition runs through the 12-language website, telephone/email booking, and the CDRS self-serve portal, while professional outreach is conducted via direct sales to multi-specialty centers, labs, and research institutions. The company has accumulated the world's largest structured molecular allergology caseload with over 95,000 subjects diagnosed, supported by the Allergome knowledge base of approximately 3,000 molecular allergens and a curated library of 138,000+ scientific articles.

Name

CAAM

Legal name

Centri Associati di Allergologia Molecolare - Studio Medico Associato

Website

https://caam-allergy.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

CAAM is a private Italian medical practice and research center specializing in molecular allergology diagnostics, serving patients and clinical partners with proprietary nanotechnology tests (FABER, ALEX3), the Allergome allergen knowledge platform, and the CDRS digital reporting system.

Ownership category

akta.pro rank

Product category

Molecular Allergy Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF)

Keywords

• Molecular allergy diagnostics
• Allergology clinical services
• Allergy blood testing
• Molecular immunology research
• Allergy diagnostic services

Headquarters

HQ city

Sermoneta

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Allergy Diagnostic Testing: Revenue from performing FABER tests and other molecular allergy diagnostics at their laboratory (Sermolab S.r.l.). Tests can be booked directly by patients or through the CAAM network of centers.
2. CDRS Subscription: Free CDRS access for one year from last test date. Extension of visualization period available through yearly subscription payment.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

CAAM operates a network of specialized molecular allergology centers in Italy that perform advanced molecular allergy diagnosis using the proprietary FABER nanotechnology test (244 allergens) and the ALEX3 test (300 allergens) from a single blood draw. The organization supports clinical work with the Allergome allergen knowledge platform, the CDRS digital reporting system, and the InterAll electronic health record, and provides a research foundation in molecular allergology through long-term collaborations with leading European institutions.

Product overview

CAAM offers a molecular allergology diagnostic platform centered on the FABER test (a multiplex nano-technology-based IgE detection system), complemented by the newer ALEX3 test (300 allergens). Patient-facing results are delivered via CDRS and CDRS PRO for professional use. The ecosystem includes the Allergome web platform for allergen knowledge, InterAll electronic medical record, and ReTiME module—all providing structured data management, real-time updates, and cross-referenced scientific information.

Differentiator

Problem solved

Functional benefit

Brands

• CDRS: CAAM Digital Reporting System - a dynamic visualization tool for allergy test results accessible to patients and professionals.
• CDRS PRO
• FABER
• ALEX3
• Allergome
• InterAll
• ReTiME

Products and services

• FABER Test In vitro diagnostic test for measuring specific IgE in human serum or plasma, using nanotechnology to conjugate hundreds of purified allergenic molecules and allergen extracts with chemically activated nanoparticles distributed in a solid-phase matrix. Used by patients and clinicians for precise molecular allergy diagnosis.
• ALEX3 Test Advanced multiplex molecular allergy test that analyzes 300 allergens simultaneously from a single blood sample, used for comprehensive molecular allergy diagnosis.
• CDRS (CAAM Digital Reporting System) Online dynamic visualization system that allows registered patients to view their allergy test results in real time, displaying data, graphs, images and comments generated dynamically from the Allergome platform and its modules. Free for one year from the last test date, with extension available through a yearly subscription. Available in 7 languages.
• CDRS PRO Professional version of the CAAM Digital Reporting System for allergists and healthcare providers, allowing visualization and management of patient allergy test results with clinical interpretation support.

Quantifiable outcome

• Over 95,000 patients diagnosed with molecular precision from 0 to 104 years of age
• +1 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core, major and regional.

• IBBR-CNR (Institute of Bioscience and Bioresources, Consiglio Nazionale delle Ricerche, Napoli)coreStrategic or Co-development PartnerResearch laboratory directed by Prof. Maria Antonietta Ciardiello. IBBR-CNR performs protein extract preparations, allergen identification and characterization including sequencing. Platinum Project Partner of the Allergome platform and developing partner of the FABER diagnostic test, producing exclusive allergenic molecules and verified allergen extracts.
• Allergy Data Laboratories (ADL) S.r.l.coreStrategic or Co-development PartnerCreated and maintains the Allergome platform since 2003. Developed InterAll electronic health record, CDRS dynamic visualization system, and ReTiME database. Platinum Project Partner of the Allergome platform.
• IFARAI Onlus (International Fund for Advanced Research in Allergy and Immunology)coreStrategic or Co-development PartnerNon-profit organization supporting research in allergic and immunologic diseases. Supports young researchers and specific research projects including AllergomeConsumer. Platinum Project Partner of the Allergome Platform.
• MacroarrayDxcoreTechnology or IntegrationTechnology partner that developed the FABER nanotechnology test system. The patented technology uses nanoparticles activated with chemical conjugation for allergen detection.
• Medical University of Vienna - Division of ImmunopathologymajorStrategic or Co-development PartnerInternational benchmark for molecular biology of allergens directed by Prof. Rudolf Valenta. Birch and grass pollen allergens were identified and cloned here, now used in allergy diagnosis and immunotherapy vaccine trials.
• University of Salzburg - Department of Molecular BiologymajorStrategic or Co-development PartnerResearch center directed by Prof. Fatima Ferreira studying allergen structures and functions with a team of molecular biologists.
• Academic Medical Center Amsterdam - Department of Experimental ImmunologymajorStrategic or Co-development PartnerDirected by Prof. Ronald van Ree, engaged in allergen characterization, epidemiology, and international standards. Coordinator of EU CREATE and FAST projects.
• International FABER PartnersregionalChannel Partner/ Reseller/ DistributorGlobal network of international partners for the FABER test including partners in France, Poland, Croatia, Romania, Spain, Austria, China, Greece and other countries mentioned in the translation credits.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ALK-Abelló: Danish allergy immunotherapy and diagnostics company. Comparable to CAAM as a specialty allergy-focused organization with both diagnostic and therapeutic development capabilities; broader and publicly listed.
• EUROIMMUN (PerkinElmer): Major European specialty diagnostics manufacturer with allergy and autoimmunity test panels. Comparable in offering multiplex IgE detection assays used by clinical laboratories, now part of PerkinElmer.
• Siemens Healthineers: Operates a broad allergy and autoimmune diagnostics portfolio (including 3gAllergy and ADVIA Centaur) used in clinical laboratories worldwide. Overlaps with CAAM's molecular allergy testing in hospital and reference lab settings.
• Thermo Fisher Scientific — ImmunoCAP / Phadia: Global leader in allergy diagnostics via the ImmunoCAP and ISAC multiplex molecular platforms. Competes directly with FABER/ALEX3 in component-resolved diagnostics and dwarfs CAAM in commercial reach and R&D budget.
• Stallergenes Greer: Global allergy immunotherapy and diagnostics player headquartered in Europe. Overlaps with CAAM in molecular allergy characterization used to guide immunotherapy patient selection.

Regional players

• R-Biopharm: German specialty diagnostics company with food and clinical allergy testing products. Comparable in component-resolved allergy diagnostics, primarily serving DACH-region laboratories.

Direct peers

• HYCOR Biomedical: US-based allergy and autoimmune diagnostics company offering IgE testing platforms. Comparable as a specialty clinical allergy diagnostics provider focused on in-vitro IgE measurement.
• MacroarrayDx: Developer of the FABER nano-bead multiplex IgE test that CAAM offers clinically. The closest comparable entity — same product platform, same scientific lineage — though it operates as the technology/manufacturer while CAAM is the clinical channel.
• Omega Diagnostics: UK-based diagnostics company with a dedicated allergy and food intolerance testing portfolio (including Allersys). Comparable as a smaller, specialty-focused allergy diagnostics provider competing for lab contracts.

Others

• Allergy Data Laboratories (ADL): Creator and maintainer of the Allergome platform and InterAll/CDRS/ReTiME modules — CAAM's core technology partner since 2003. Operationally adjacent rather than competitive; key ecosystem enabler.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CAAMAllergy
• Facebookfacebook.com/CAAMallergy
• LinkedInlinkedin.com/company/caam---centro-associati-di-allergologia-molecolare

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CAAM